Teva Pharmaceutical Industries Announces New Data Highlighting Significant Gap In Diagnosing Tardive Dyskinesia In Teen Patients With Underlying Mood Disorders

Teva Pharmaceutical Industries Limited Sponsored ADR

Teva Pharmaceutical Industries Limited Sponsored ADR

TEVA

0.00

The IMPACT-TD findings revealed:

  • A majority of participants, regardless of age, reported a moderate to severe global impact from TD. This burden was particularly high for those aged 18-29 (85%) and 50-59 (87%, n=57), demonstrating that TD significantly affects daily life across the adult lifespan.
  • The psychological impact of TD was most pronounced in adults aged <60. Over three-quarters (77%) of those aged 18-29 experienced moderate to severe psychological effects despite lower AIMS scores (6.4) on average compared to older adults aged 60-69 (8.4, n=56) and >69 (9.9, n=28).
  • Despite the high impact, formal TD diagnosis rates were lowest among adults <40 years old. The rate was 23% for participants aged 18-29 and 35% for participants aged 30-39 (n=20), well below the peak of 57% seen in adults aged 40-49 (n=37) and 47% average in the 50+ age subgroups.
  • A significant delay in diagnosis was also identified, with patients waiting an average of more than 3.5 years to be formally diagnosed after their involuntary movements were first recognized.